Jennifer Lachey, Chief Scientific Officer at Keros Therapeutics, Inc. (KROS), sold 2,650 shares at $50.00 ($133K) on 2021-05-11, disclosed to the SEC on 2021-05-13.
Open-market sale of $132k KROS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| KROS | SELL | 2022-05-13 | $362K | — | Filing → |
| KROS | SELL | 2022-04-13 | $630K | — | Filing → |
| KROS | SELL | 2022-04-06 | $477K | — | Filing → |